Physician profile
Roy Gallinger
NPI 1235101858
$6,445.58
in general payments reported to CMS, 2019-2025
34 companies · $588 in 2025
The $588 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,642 · 2020: $1,794 · 2021: $1,247 · 2022: $125 · 2023: $343 · 2024: $706 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,637.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,033.81 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $702.95 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $689.81 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $520.49 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $449.58 | 2019-2022 | |
| Glaxosmithkline, LLC. | $427.61 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $410.98 | 2019-2025 | Xifaxan |
| Abbvie INC. | $340.69 | 2019-2025 | |
| Lilly USA, LLC | $325.23 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $262.14 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $232.06 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $218.39 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $104.92 | 2019-2021 | |
| Exact Sciences Corporation | $98.06 | 2024-2025 | Cologuard Collection Kit |
| Allergan, INC. | $91.39 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $64.04 | 2021-2024 | |
| Abbott Laboratories | $52.47 | 2020-2021 | |
| Eisai INC. | $47.16 | 2021 | |
| Amarin Pharma, INC. | $46.77 | 2019 | |
| Astellas Pharma US INC | $34.09 | 2020-2021 | |
| Esperion Therapeutics, INC. | $32.27 | 2020 | |
| Hologic Sales and Service, LLC | $31.07 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.90 | 2019 | |
| Ironshore Pharmaceuticals INC. | $28.93 | 2019 | |
| Inspire Medical Systems, INC. | $26.34 | 2025 | Inspire |
| Corcept Therapeutics | $18.49 | 2024 | Korlym |
| Dexcom, INC. | $18.25 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.94 | 2025 | Voquezna |
| Ultragenyx Pharmaceutical INC. | $17.39 | 2020 | |
| Radius Health, INC. | $16.73 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $15.60 | 2021 | |
| Smith+Nephew, INC. | $14.03 | 2024 | Collagenase Santyl |
| Novartis Pharmaceuticals Corporation | $13.58 | 2021 | |
| Gilead Sciences, INC. | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Gallinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.